Roche teases 'encouraging' Phase 1 data for weight loss drug from $2.7B Carmot buyout
Roche offered a glimpse at promising early efficacy data on Thursday morning from a GLP-1/GIP agonist it obtained as part of its $2.7 billion acquisition …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.